Solutions OP Clinical Trials UK Podcast Por Olga Peycheva arte de portada

Solutions OP Clinical Trials UK

Solutions OP Clinical Trials UK

De: Olga Peycheva
Escúchala gratis

This podcast is dedicated to clinical trials and clinical research. We will be discussing different hot topics and analysis of the latest developments in clinical trials in pharmaceutical and medical devices industries. We have interviews with different industry experts.

New episodes will be available every 2 weeks.

Solutions OP LTD
Economía Enfermedades Físicas Gestión Gestión y Liderazgo Higiene y Vida Saludable
Episodios
  • Clinical Research Opportunities in Japan: Interview with Tetsu Yung
    Apr 3 2026

    In this episode we are discussing the clinical research opportunities in Japan. Our guest is Tetsu Yung who is a consultant with extensive experience in pharma and CRO industry in Japan. We cover the main requirements for setting up clinical trials in Japan and the timelines for obtaining approvals. We also talk about initiatives from the Japanese government to encourage pharma start-ups to set up in Japan and conduct their clinical research in the country.

    Más Menos
    38 m
  • Do We Need Animal Testing: Overview with Lydia Ainsworth
    Mar 20 2026

    In this episode we are talking with our Senior Clinical Data Quality Manager, Lydia Ainsworth, about animal testing in clinical research.

    Join us to learn:

    • What are the most common animals used in animal testing,
    • The typical cost for using animals in clinical research,
    • The ethical issues around using animals,
    • When animal testing is needed in drug development
    • What are the alternatives of animal testing.
    Más Menos
    25 m
  • The Latest Drug Development Trends In The Pharma Industry In 2026
    Mar 6 2026

    This episode is an analysis of the latest investment trends in research and development in the pharma industry in 2026. You can learn what has changed in clinical research and the way companies invest in developing new drug products. It touches on investment risks, price pressure and the threat from biosimilars.

    Más Menos
    23 m
Todavía no hay opiniones